【摘要】 目的 利用标准源物理半衰期而得理论标准源计数，计算甲状腺摄碘率的可行性。 方法 2009年3—9月，通过实际测量标准源计数与利用标准源物理衰变速率计算的理论标准源计数的方法，分别计算209例甲状腺功能亢进症患者服用131I 370 kBq 4、24 h甲状腺摄取率，行配对t检验分析实测与计算所得甲状腺摄取率有无差异。 结果 实测标准源计数与理论标准源计数计算所得的甲状腺4 h摄碘率分别为32%±16%、35%±10%，差异无统计学意义（t=1.98，P=0.20）；24 h摄碘率分别为72%±19%、69%±24%，差异无统计学意义（t=1.49，P=0.23）。 结论 利用标准源物理衰变速率计算甲状腺的摄碘率是可行的。
Citation：
曾宇,周绿漪. 利用标准源物理衰变率计算甲状腺摄碘率. West China Medical Journal, 2011, 26(6): 930-931. doi:
Copy
Copyright © the editorial department of West China Medical Journal of West China Medical Publisher. All rights reserved
| 1. |
Franklyn JA. What is the role of radioiodine uptake measurement and thyroid scintigraphy in the diagnosis and management of hyperthyroidism[J]. Clin Endocrinol, 2010, 70(1): 11-12.
|
| 2. |
中华医学会临床技术操作规范核医学分册[M]. 北京: 人民军医出版社, 2004: 79-80.
|
| 3. |
匡安仁, 李林. 核医学[M]. 北京: 高等教育出版社, 2008: 88-89.
|
| 4. |
Merrill S, Horowitz J, Traino AC, et al. Accuracy and optimal timing of activity measurements in estimating the absorbed dose of radioiodine in the treatment of Graves’ disease[J]. Phys Med Biol, 2011, 56(3): 557-571.
|
| 5. |
Ross DS. Radioiodine therapy for hyperthyroidism[J]. N Engl J Med, 2011, 364(6): 542-550.
|
| 6. |
AlSharif AA, Abujbara MA, Chiacchio S, et al. Contribution of radioiodine uptake measurement and thyroid scintigraphy to the differential diagnosis of thyrotoxicosis[J]. Hell J Nucl Med, 2010, 13(2): 132-137.
|
| 7. |
Traino AC, Grosso M, Mariani G. Possibility of limiting the un-justified irradiation in 131I therapy of Graves’ disease: a thyroid mass-reduction based method for the optimum activity calculation[J]. Phys Medica, 2010, 26(2): 71-79.
|
| 8. |
Van Isselt JW, Broekhuizen-de Gast HS. The radioiodine turnover rate as a determinant of radioiodine treatment outcome in Graves’ disease[J]. Hell J Nucl Med, 2010, 13(1): 2-5.
|
| 9. |
Salvatori M, Luster M. Radioiodine therapy dosimetry in benign thyroid disease and differentiated thyroid carcinoma[J]. Euro J Nucl Med Mol Imaging, 2010, 37(4): 821-828.
|
| 10. |
Kobe C, Eschner W, Wild M, et al. Radioiodine therapy of benign thyroid disorders: what are the effective thyroidal half-life and uptake of 131I? [J]. Nucl Med Commun, 2010, 31(3): 201-205.
|
- 1. Franklyn JA. What is the role of radioiodine uptake measurement and thyroid scintigraphy in the diagnosis and management of hyperthyroidism[J]. Clin Endocrinol, 2010, 70(1): 11-12.
- 2. 中华医学会临床技术操作规范核医学分册[M]. 北京: 人民军医出版社, 2004: 79-80.
- 3. 匡安仁, 李林. 核医学[M]. 北京: 高等教育出版社, 2008: 88-89.
- 4. Merrill S, Horowitz J, Traino AC, et al. Accuracy and optimal timing of activity measurements in estimating the absorbed dose of radioiodine in the treatment of Graves’ disease[J]. Phys Med Biol, 2011, 56(3): 557-571.
- 5. Ross DS. Radioiodine therapy for hyperthyroidism[J]. N Engl J Med, 2011, 364(6): 542-550.
- 6. AlSharif AA, Abujbara MA, Chiacchio S, et al. Contribution of radioiodine uptake measurement and thyroid scintigraphy to the differential diagnosis of thyrotoxicosis[J]. Hell J Nucl Med, 2010, 13(2): 132-137.
- 7. Traino AC, Grosso M, Mariani G. Possibility of limiting the un-justified irradiation in 131I therapy of Graves’ disease: a thyroid mass-reduction based method for the optimum activity calculation[J]. Phys Medica, 2010, 26(2): 71-79.
- 8. Van Isselt JW, Broekhuizen-de Gast HS. The radioiodine turnover rate as a determinant of radioiodine treatment outcome in Graves’ disease[J]. Hell J Nucl Med, 2010, 13(1): 2-5.
- 9. Salvatori M, Luster M. Radioiodine therapy dosimetry in benign thyroid disease and differentiated thyroid carcinoma[J]. Euro J Nucl Med Mol Imaging, 2010, 37(4): 821-828.
- 10. Kobe C, Eschner W, Wild M, et al. Radioiodine therapy of benign thyroid disorders: what are the effective thyroidal half-life and uptake of 131I? [J]. Nucl Med Commun, 2010, 31(3): 201-205.
